{"id":389305,"date":"2022-12-29T00:00:00","date_gmt":"2022-12-29T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0010-2022-biopharma-squamous-cell-carcinoma-of-the-head-and-neck-disease-landscape-forecast-g7-2022\/"},"modified":"2026-04-29T05:18:29","modified_gmt":"2026-04-29T05:18:29","slug":"dlsfon0010-2022-biopharma-squamous-cell-carcinoma-of-the-head-and-neck-disease-landscape-forecast-g7-2022","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0010-2022-biopharma-squamous-cell-carcinoma-of-the-head-and-neck-disease-landscape-forecast-g7-2022\/","title":{"rendered":"Squamous Cell Carcinoma of the Head and Neck | Disease Landscape &#038; Forecast | G7 | 2022"},"content":{"rendered":"<p>The treatment landscape for squamous cell carcinoma of the head and neck (SCCHN) witnessed a major change in 2019 with the approval of Merck &#038; Co.\u2019s Keytruda for untreated recurrent or metastatic SCCHN. For nearly a decade, the EGFR inhibitor Erbitux (Eli Lilly \/ Merck KGaA) was the cornerstone in the treatment algorithm. Immune checkpoint inhibitors (e.g., Keytruda, Bristol Myers Squibb \/ Ono Pharmaceutical\u2019s Opdivo) are also prescribed in later lines, where competition is fierce. Although SCCHN has historically been a complex challenge for drug developers, many immuno-oncology treatment approaches and other drug classes are in the late-phase pipeline for both metastatic and early-stage settings. Several agents are positioned to treat the untapped and lucrative locoregionally advanced SCCHN, fueling market growth over the 2021-2031 forecast period.<\/p>\n<p><strong>Questions answered <\/strong><\/p>\n<ul>\n<li>What is the current treatment algorithm for locoregionally advanced and recurrent or metastatic SCCHN in the major pharmaceutical markets? What are interviewed experts\u2019 views on current and emerging late-phase therapies?<\/li>\n<li>How large are the clinically and commercially relevant drug-treatable SCCHN populations, and how will drug-treatment rates change over the 2021-2031 forecast period?<\/li>\n<li>What market and patient share can agents in late-phase development for SCCHN expect to secure?<\/li>\n<li>What are the key drivers of and constraints on the SCCHN therapy market, and how will these factors change over the 10-year forecast period?<\/li>\n<\/ul>\n<p><strong>Product description <\/strong><\/p>\n<p>Disease Landscape &#038; Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><strong>Solution enhancement<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.<\/p>\n","protected":false},"template":"","class_list":["post-389305","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-oncology","biopharma-therapy-areas-squamous-cell-carcinoma-of-the-head-and-neck","biopharma-geography-us","biopharma-date-960"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389305","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389305\/revisions"}],"predecessor-version":[{"id":576139,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389305\/revisions\/576139"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389305"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}